CVR 36392290Public limited company (A/S)Engroshandel med læge- og hospitalsartikler (464620)Vallensbæk StrandFounded 29 Sep 2014
Compiled by Dandex from the Danish Business Registry (CVR, datacvr.virk.dk), Erhvervsstyrelsen, and annual reports filed in XBRL. Values marked Dandex estimate are computed by Dandex from that data, not registered.
Dandex is Danish Company Data. Connect it once and ask about Shire Denmark A/S, or any Danish company, from your assistant, the API or the command line. Answers come from the current record: owners and the ownership network, financials year by year, and the latest registered changes.
Set up DandexEmployees
15
CVR, 2020
Result
+2.3M
DKK, annual report 2018
Equity
31.2M
DKK, annual report 2018
Takeda Pharmaceuticals International AG100% of capital and votes, until 1 Apr 2020
Lars Patrik Mikael Forselluntil 1 Apr 2020
No current owner is registered.
100% of capital and votes1 May 2015 to 7 May 2015
100% of capital and votesnotified 6 Jan 20208 May 2015 to 6 Jan 2020
100% of capital and votes6 Jan 2020 to 1 Apr 2020
Shire Denmark A/S holds no Danish company now.
Danish companies held at 5% or more, from the CVR owner register (ejerregister), and their holdings one level down. Foreign holdings are not in CVR.
CVR 33358008100% of capital and votes26 Mar 2018 to 1 Apr 2018
Decided by Dandex from CVR and the filed annual reports, not registered by the company.
Fixed rules decide most of these. The auditor's report, the business model, the revenue model and the activity in its own words are read by a calibrated decision model from the report's text and the purpose clause. Each label links to its definition.
CVR lists no current officers for this company.
CVR records founders at incorporation. It does not record whether they are alive or still involved.
Mar 2020, monthly: 15 employees, 15 FTE
Arrow keys move through the periods, Home and End go to the first and the latest, Escape returns to the latest.
| Period | May 2015 | Jun 2015 | Jul 2015 | Aug 2015 | Sep 2015 | Oct 2015 | Nov 2015 | Dec 2015 | Jan 2016 | Feb 2016 | Mar 2016 | Apr 2016 | May 2016 | Jun 2016 | Jul 2016 | Aug 2016 | Sep 2016 | Oct 2016 | Nov 2016 | Dec 2016 | Jan 2017 | Feb 2017 | Mar 2017 | Apr 2017 | May 2017 | Jun 2017 | Jul 2017 | Aug 2017 | Sep 2017 | Oct 2017 | Nov 2017 | Dec 2017 | Jan 2018 | Feb 2018 | Mar 2018 | Apr 2018 | May 2018 | Jun 2018 | Jul 2018 | Aug 2018 | Sep 2018 | Oct 2018 | Nov 2018 | Dec 2018 | Jan 2019 | Feb 2019 | Mar 2019 | Apr 2019 | May 2019 | Jun 2019 | Jul 2019 | Aug 2019 | Sep 2019 | Oct 2019 | Nov 2019 | Dec 2019 | Jan 2020 | Feb 2020 | Mar 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Employees | 5 | 5 | 6 | 6 | 8 | 8 | 8 | 8 | 8 | 9 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 6 | 6 | 6 | 6 | 6 | 7 | 6 | 6 | 6 | 5 | 5 | 15 | 13 | 12 | 13 | 13 | 13 | 11 | 11 | 11 | 11 | 10 | 9 | 10 | 10 | 9 | 9 | 9 | 10 | 13 | 15 | 15 | 15 | 15 | 15 |
| FTE | 4 | 4 | 5 | 5 | 7 | 7 | 7 | 7 | 7 | 8 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 5 | 5 | 5 | 5 | 5 | 6 | 5 | 5 | 5 | 4 | 4 | 13 | 12 | 11 | 12 | 12 | 11 | 10 | 10 | 10 | 10 | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 9 | 12 | 15 | 15 | 15 | 15 | 15 |
| Series | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly |
The legal entity's headcount in CVR, not the annual report's average, which may cover a group. CVR changed its monthly method in Oct 2019: a step there need not be real.
Source: CVR, latest Mar 2020, published 26 May 2020.
The company's own figures, in DKK, from the annual reports filed in XBRL.
2018, DKK: Revenue not reported, Operating profit 3M, Result for the year 2.3M
Arrow keys move through the years, Home and End go to the first and the latest, Escape returns to the latest.
2018, DKK: Total assets 87.8M, Equity 31.2M
Arrow keys move through the years, Home and End go to the first and the latest, Escape returns to the latest.
| DKK thousands | 2014 | 2015 | 2016 | 2017 | 2018 |
|---|---|---|---|---|---|
| Revenue | Not reported | 18,614 | 23,889 | 16,217 | Not reported |
| Operating profit | Not reported | +2,588 | +3,092 | +2,746 | +3,011 |
| Result for the year | 0 | +1,790 | +2,246 | +2,091 | +2,284 |
| Equity | 500 | 24,596 | 26,842 | 28,932 | 31,217 |
| Total assets | 500 | 34,130 | 50,780 | 51,906 | 87,820 |
| Employees (average) | Not reported | Not reported | Not reported | 6 | Not reported |
| Credit metrics (Dandex calculations) | |||||
| Revenue growth (omsætningsvækst) | Not reportednote 1 | n.m.note 2 | 28.3% | -32.1% | Not reported |
| EBIT margin (overskudsgrad) | Not reported | 13.9% | 12.9% | 16.9% | Not reported |
| EBITDA | Not reportednote 3 | 2,832 | 3,585 | 3,354 | 3,772 |
| EBITDA margin (EBITDA-margin) | Not reported | 15.2% | 15% | 20.7% | Not reported |
| Employee growth (vækst i antal ansatte) | Not reportednote 4 | Not reportednote 4 | Not reportednote 4 | -25% | Not reportednote 4 |
| Net interest-bearing debt (NIBD, nettorentebærende gæld)Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. | Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. | ||||
| Gearing, NIBD / EBITDAPro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. | Pro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. | ||||
| Interest coverage (rentedækning)Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. | Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. | ||||
| Adjusted equity ratio (justeret soliditetsgrad)Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. | Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. | ||||
| ROIC (afkast af investeret kapital)Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. | Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. | ||||
| Capex (investeringer i anlægsaktiver) | Not reportednote 5 | 0note 6 | 2,219note 7 | 58note 8 | 1,490note 7 |
| Capex % of sales (investeringer i procent af omsætningen)Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. | Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. | ||||
| FCFF / EBITDA (pengestrømskonvertering)Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. | Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. | ||||
Not every period is a full year: 2014 covers 3 months (29 Sep to 31 Dec 2014). Changes against it compare periods of different length.
Credit metrics are Dandex calculations, not filed values; grey figures are estimates with a note. Definitions.
How each credit metric is calculated:
No changes since Dandex began following this company. For announcements from before then, see Registrations.
Pro: Signals (signaler) are in the Pro plan, see pricingChanges worth a look, raised from the registry and new annual reports.
New leadership (nyt lederskab), New company (ny virksomhed), Ownership change (ejerskifte), Relocation (flytning), Growth surge (vækstspurt), Headcount decline (nedgang i ansatte), Restructuring (omstrukturering), Industry change (brancheskift), Board change (bestyrelsesændring), Dissolution (ophør), Distress warning (risikoadvarsel), Fund investment (fondsinvestering), Fund exit (fondsexit), Fund board seat (fondsbestyrelsespost).
What Pro holds for Shire Denmark A/S:
Have Pro? Sign in.
Amounts in DKK.
| Date | Change | Cash price | Paid in | Implied value | Capital after |
|---|---|---|---|---|---|
| IncreaseAn existing businessPaid in 22,306,000 | None | 22,306,000 | None | 600,000 | |
| FoundingCashPaid in 500,000 | None | 500,000 | None | 500,000 |
Source: Erhvervsstyrelsen's announcements, shown where the amounts add up to the registered capital.
Merger (fusion), as the ceasing company (ophørende selskab)
Merger (fusion), as the continuing company (fortsættende selskab)
Source: CVR, read 17 Nov 2026.
Counts include corrections, and an audit firm that re-registered under a new entity.
Source: CVR, read 17 Nov 2026.
21 registrations, as published by Erhvervsstyrelsen. People's street addresses are cut to postcode and city.
Erhvervsstyrelsen har modtaget oplysning om, at der er truffet beslutning om nedenstående fusion.
Virksomheden er d. 01.04.2020 opløst ved fusion med CVR-nummer: 16406899 TAKEDA PHARMA A/S.
Erhvervsstyrelsen har modtaget fusionsplan for den påtænkte fusion mellem CVR-nummer: 16406899 TAKEDA PHARMA A/S (fortsættende), der tillige driver virksomhed under navnene NYCOMED DANMARK A/S, DAK LABORATORIES A/S, NYCOMED DAK A/S, NYCOMED DK A/S, BENZON BIOSYSTEMS A/S, BENZON PHARMA A/S, BENZON BIO-TECH A/S, NYCOMED PHARMA A/S, BASODERM A/S, NYCOMED PHARMA-MEDICA A/S, PHARMA-MEDICA A/S, AB PHARMA A/S, DANIMED A/S, NYCOMED BENZON A/S, TAKEDA PHARMACEUTICALS DENMARK A/S, Nettopharma A/S, Pharmachemie A/S, Nycomed Consumer A/S og CVR-nummer: 36392290 Shire Denmark A/S (ophørende).
Der er endvidere modtaget erklæring fra vurderingsmændene om, at kreditorerne i CVR-nummer: 16406899 TAKEDA PHARMA A/S og CVR-nummer: 36392290 Shire Denmark A/S må antages at være tilstrækkeligt sikrede efter fusionen.
Ny adresse: c/o Takeda Pharma A/S, Delta Park 45, 2665 Vallensbæk Strand
Ny kommune: Vallensbæk
Vedtægter ændret: 20.06.2019
Revision:
Fratrådte:
DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB, den 20.06.2019.
Tiltrådte:
CVR-NR. 25578198 KPMG P/S, Dampfærgevej 28, 2100 København Ø, den 20.06.2019.
Regnskabsår ændret til: 01.04 - 31.03
Omlægningsperiode: 01.01.2019 - 31.03.2020
Bestyrelse:
Fratrådte:
Eduardo Kneese, den 01.07.2019, Kerstin Anna-Lena Engvall, (formand), den 01.07.2019.
Tiltrådte:
Christian Ramskov, (formand), den 30.08.2019, Lars Patrik Mikael Forsell, den 30.08.2019.
Direktion:
Fratrådte:
Anders Pode Milwertz, (adm. dir), den 01.07.2019.
Tiltrådte:
Lars Patrik Mikael Forsell, (adm. dir), den 30.08.2019.
Direktion:
Fratrådte:
Jacob Fredrik Westin (adm. dir), den 16.10.2018.
Tiltrådte:
Anders Pode Milwertz (adm. dir), den 16.10.2018, Jacob Fredrik Westin, den 16.10.2018.
Bestyrelse:
Fratrådte:
Johan Åke Östen Pettersson, den 24.05.2018.
Tiltrådte:
Eduardo Kneese, den 24.05.2018.
Erhvervsstyrelsen har modtaget oplysning om, at der er truffet beslutning om nedenstående fusion.
Virksomheden er fusioneret med CVR-nummer: 33358008 Shire Biotech Denmark ApS, der samtidigt er opløst.
Erhvervsstyrelsen har modtaget fusionsplan for den påtænkte fusion mellem CVR-nummer: 36392290 Shire Denmark A/S (fortsættende) og CVR-nummer: 33358008 Shire Biotech Denmark ApS (ophørende).
Der er endvidere modtaget erklæring fra vurderingsmændene om, at kreditorerne i CVR-nummer: 36392290 Shire Denmark A/S og CVR-nummer: 33358008 Shire Biotech Denmark ApS må antages at være tilstrækkeligt sikrede efter fusionen.
Ny adresse: Larsbjørnsstræde 3, 1454 København K
Ny kommune: København
Vedtægter ændret: 01.08.2017
Nyt navn: Shire Denmark A/S
Direktion:
Fratrådte:
Anders Pode Milwertz, den 29.05.2017.
Tiltrådte:
Jacob Fredrik Westin (adm. dir), den 29.05.2017.
Bestyrelse:
Fratrådte:
Anders Pode Milwertz, den 08.05.2017, Philippe David Alexandre Mendels-Flandre, den 08.05.2017, Jens Harpøth Zilstorff (formand), den 08.05.2017.
Tiltrådte:
Jacob Fredrik Westin, den 08.05.2017, Johan Åke Östen Pettersson, den 08.05.2017, Kerstin Anna-Lena Engvall (formand), den 08.05.2017.
Direktion:
Fratrådte:
.
Revision:
Fratrådte:
PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB, den 31.12.2016.
Tiltrådte:
CVR-NR. 33963556 DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB, Weidekampsgade 6, 2300 København S, den 01.01.2017.
CVR-nummer:
36392290.
NAVN:
BAXALTA DENMARK A/S.
Adresse: Tobaksvejen 2A, 2860 Søborg.
Kommune: Gladsaxe.
Bestyrelse:
Fratrådte:
Jan Ulrik Stevnsborg, den 16.06.2015, Bo Magnus Lindholm, den 16.06.2015.
Tiltrådte:
Anders Pode Milwertz, den 16.06.2015, Philippe David Alexandre Mendels-Flandre, den 16.06.2015.
Direktion:
Fratrådte:
Jan Ulrik Stevnsborg, den 16.06.2015.
Tiltrådte:
Anders Pode Milwertz, den 16.06.2015.
CVR-nummer:
36392290.
NAVN:
BAXALTA DENMARK A/S.
Adresse: Tobaksvejen 2A, 2860 Søborg.
Kommune: Gladsaxe.
Vedtægter ændret: 01.06.2015
CVR-nummer:
36392290.
NAVN:
BAXALTA DENMARK A/S.
Adresse: Gydevang 43, 3450 Allerød.
Kommune: Allerød.
Ny adresse: Tobaksvejen 2A, 2860 Søborg
Ny kommune: Gladsaxe
CVR-nummer
36392290.
NAVN:
BAXALTA DENMARK A/S.
Adresse: Gydevang 43, 3450 Allerød.
Kommune: Allerød.
Vedtægter ændret: 30.04.2015
Kapitalforhøjelse: kr. 100.000,00, indbetalt ved indskud af bestående virksomhed, kurs 22.306,00.
Kapitalen udgør herefter kr. 600.000,00.
CVR-nummer
36392290.
NAVN:
BAXALTA DENMARK A/S.
Adresse: Gydevang 43, 3450 Allerød.
Kommune: Allerød.
Bestyrelse:
Fratrådte:
Robert Gunnar Ström, den 11.03.2015.
Tiltrådte:
Bo Magnus Lindholm, den 11.03.2015.
Stiftelsesdato:
29.09.2014.
Seneste vedtægtsdato:
29.09.2014.
Kapital:
kr. 500.000,00.
Indbetalingsmåde:
Indbetalt kontant kr. 500.000,00 til kurs 100,00.
Stifter:
CVR-NR. 72246012 BAXTER A/S, Gydevang 43, 3450 Allerød, den 29.09.2014.
Bestyrelse:
Advokat Jens Harpøth Zilstorff (formand), den 29.09.2014, Cand pharm Jan Ulrik Stevnsborg, den 29.09.2014, Robert Gunnar Ström, den 29.09.2014.
Direktion:
Cand pharm Jan Ulrik Stevnsborg, den 29.09.2014.
Selskabet tegnes af enten 1) bestyrelsesformanden, 2) direktøren eller 3) af 2 bestyrelsesmedlemmer i forening.
Revision:
CVR-NR. 33771231 PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB, Strandvejen 44, 2900 Hellerup, den 29.09.2014.
Første regnskabsår:
29.09.2014 - 31.12.2014.
Regnskabsår:
01.01 - 31.12.
P-number 1024547422Delta Park 45, 2665 Vallensbæk Strand
P-number 1019755912Delta Park 45, 2665 Vallensbæk Strand